The FDA ordered warnings of mental health risks on the labels of Pfizer's Chantix and GlaxoSmithKline's Zyban in light of reports linking the smoking-cessation drugs to behavioral changes, depression, hostility and suicidal thoughts. Pfizer said it has already made the risk information available to health care providers and patients by updating Chantix's label in accordance with FDA guidelines.

Full Story:

Related Summaries